Author

Ziv Frankenstein

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

Alexander R.A. AndersoniD· 1 shared Artem Kaznatcheev· 1 shared Arturo Araujo· 1 shared Benedikt Bauer· 1 shared David BasantaiD· 1 shared David Robert Grimes· 1 shared Douglas W. StrandiD· 1 shared Ernesto A. B. F. Lima· 1 shared

Activity by Year

2016-2017 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander R.A. AndersonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Stromal Reactivity Differentially Drives Tumor Cell Evolution and Prostate Cancer Progression

Ziv Frankenstein, David Basanta, Omar E. Franco, Yan Gao, Rodrigo A. Javier, Douglas W. Strand, MinJae Lee, Simon W. Hayward, Gustavo Ayala, Alexander R.A. Anderson

This study develops a hybrid model showing stromal reactivity influences prostate cancer progression and prognosis by shaping tumor cell evolution and aggressiveness.

bioRxiv · Aug 21, 2017 · PreprintCancer Biology

Toxicity Management in CAR T cell therapy for B-ALL: Mathematical modelling as a new avenue for improvement.

Shalla Hanson, David Robert Grimes, Jake P. Taylor-King, Benedikt Bauer, Pravnam I. Warman, Ziv Frankenstein, Artem Kaznatcheev, Michael J. Bonassar, Vincent L. Cannataro, Zeinab Y. Motawe, Ernesto A. B. F. Lima, Sungjune Kim, Marco L. Davila, Arturo Araujo

This paper develops a mathematical model to explore toxicity in CAR T cell therapy for B-ALL, finding that initial tumour burden is a stronger predictor of toxicity than CAR T cell dose.

bioRxiv · Apr 22, 2016 · PreprintCancer Biology